Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enrico Breda

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
The Lancet. Oncology|February 4, 2021
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trialSandro Pignata, Domenica Lorusso, Florence Joly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trialSandro Pignata, Giovanni Scambia, Gabriella Ferrandina, et al.
The Lancet. Oncology|March 4, 2014
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trialSandro Pignata, Giovanni Scambia, Dionyssios Katsaros, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 1, 2021
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A studyGennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 31, 2021
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trialRaimondo Di Liello, Laura Arenare, Francesco Raspagliesi, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
The Lancet. Oncology|February 4, 2021
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trialSandro Pignata, Domenica Lorusso, Florence Joly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trialSandro Pignata, Giovanni Scambia, Gabriella Ferrandina, et al.
The Lancet. Oncology|March 4, 2014
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trialSandro Pignata, Giovanni Scambia, Dionyssios Katsaros, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 1, 2021
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A studyGennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 31, 2021
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trialRaimondo Di Liello, Laura Arenare, Francesco Raspagliesi, et al.
Pageof 3